Clinical Trial Update: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and pharmacokinetics of the transdermal Sancuso and intravenous granisetron in adolescents (ages 13-17) with chemotherapy-in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Granisetron (granisetron)
• SANCUSO (GRANISETRON)

Snippet

Sponsor: Kyowa Kirin Pharmaceutical Development Ltd | Conditions: Chemotherapy Induced Nausea and Vomiting | Phase 1 | Status: COMPLETED